Investigational drug · Phase 2
Ruzasvir
Also called: AT-038
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
19
Any phase or sponsor naming "Ruzasvir"
First trial start
2023
May 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ruzasvir", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Chronic Hepatitis C Virus
- Hepatitis C, Chronic
- Hepatitis C
- Hepatic Cirrhosis
- HCV
Approved drugs for the same conditions: Hepatitis C · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Ruzasvir" as an intervention, largest first.
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVPivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06868264 · 940 participants · Start Apr 7, 2025 · Primary completion Jun 18, 2026
Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR); Sofosbuvir-Velpatasvir (SOF/VEL) · For: HEPATITIS C VIRUS CHRONIC INFECTION
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 105 sites in all
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVPivotal-lookingActive, not recruiting
Atea Pharmaceuticals, Inc.Industry
NCT07037277 · 880 participants (planned) · Start Jun 2, 2025 · Primary completion Dec 2026
Drug: Bemnifosbuvir-Ruzasvir; Sofosbuvir-Velpatasvir · For: HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection and 1 more
Sites: Cairo, Egypt; Nice, France; Strasbourg, France · 107 sites in all
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02332707 · 443 participants · Start Jan 22, 2015 · Primary completion Sep 16, 2016
Drug: Grazoprevir; Uprifosbuvir and 4 more · For: Hepatitis C
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02332720 · 413 participants · Start Jan 28, 2015 · Primary completion Sep 19, 2016
Drug: Grazoprevir; Uprifosbuvir and 4 more · For: Hepatitis C
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02956629 · 282 participants · Start Nov 16, 2016 · Primary completion Dec 22, 2017
Drug: Uprifosbuvir; Ruzasvir and 1 more · For: Hepatitis C
Atea Pharmaceuticals, Inc.Industry
NCT05904470 · 275 participants · Start May 30, 2023 · Primary completion Dec 9, 2024
Drug: Bemnifosbuvir; Ruzasvir · For: Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C and 2 more
Sites: San Antonio, Texas; Manaus, Brazil; Salvador, Brazil · 51 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02759315 · 160 participants · Start May 3, 2016 · Primary completion Jul 27, 2017
Drug: Uprifosbuvir 450 mg; Ruzasvir 60 mg · For: Hepatitis C, Chronic
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02613403 · 94 participants · Start Dec 10, 2015 · Primary completion Jan 9, 2017
Drug: MK-3682B; Ribavirin · For: Hepatitis; Hepatitis C; Digestive System Diseases and 5 more
Atea Pharmaceuticals, Inc.Industry
NCT06204679 · 42 participants · Start Dec 14, 2023 · Primary completion Aug 25, 2024
Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions; Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions and 1 more · For: Healthy Volunteer Study
Sites: Cypress, California
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06921941 · 38 participants · Start Apr 8, 2025 · Primary completion Jul 2, 2025
Drug: Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR; Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR · For: Healthy Volunteer Study
Sites: Québec, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.
Jucov A, Conway B, Feld JJ, et al. · Hepatology 2026
- Multiscale Modeling of an 8-Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection.
Zitzmann C, Ribeiro RM, Marc A, et al. · Clin Pharmacol Ther 2026
- Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants.
Zhou XJ, Morelli G, Montrond M, et al. · Clin Pharmacol Drug Dev 2025
- Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo.
Good SS, Luo S, Lin K, et al. · Antiviral Res 2025
- Insights into the Control of Drug Release from Complex Immediate Release Formulations.
Dong R, DiNunzio JC, Regler BP, et al. · Pharmaceutics 2021
- Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance.
Alimohammadi A, Conway B, Yamamoto L · BMJ Case Rep 2020
Also in development for Chronic Hepatitis C Virus
- BemnifosbuvirAT-527Phase 21 trial
Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.